Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 2007-2014

  Ågren, Anna ^a,b   Jörneskog, Gun ^b   Elgue, Graciela ^b   Henriksson, Peter ^b   Wallen, Håkan ^b   Wiman, Björn ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; BLOOD CLOTTING FACTOR 13; D DIMER; FIBRIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; ALPHA 2 ANTIPLASMIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRIN CLOT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SEX DIFFERENCE; BLOOD; CASE CONTROL STUDY; COMPLICATION; FIBRINOLYSIS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ALPHA-2-ANTIPLASMIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84903538447     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1776     Document Type: Article

References (40)

1. Gibbons GW, Shaw PM. Diabetic vascular disease: characteristics of vascular disease unique to the diabetic patient. Semin Vasc Surg 2012;25:89-92
2. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44-54 (Pubitemid 32203891)
3. Morel O, Jesel L, Abbas M, Morel N. Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost 2013;39:477-488
4. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010;7:260-273
5. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005;165:784-789 (Pubitemid 40569432)
6. Palmerini T, Généreux P, Mehran R, et al. Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial). Am J Cardiol 2013;111:1237-1245
7. Maraschin JdeF. Classi fication of diabetes. Adv Exp Med Biol 2012;771:12-19
8. Magnuson EA, Farkouh ME, Fuster V, et al.; FREEDOMTrial Investigators. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation 2013;127:820-831
9. Libman IM, Laporte RE, Tull ES, Matsushima M. Insulin dependent diabetes mellitus in the 21st century and beyond a model disease for global health? (A review). Diabete Metab 1993;19:74-79 (Pubitemid 23151054)
10. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.Diabetologia 2003;46:760-765 (Pubitemid 36831403)
11. Leander K, Wiman B, Hallqvist J, et al.; Stockholm Heart Epidemiology Program. PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP). Thromb Haemost 2003;89:1064-1071 (Pubitemid 36798159)
12. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in youngmen. Br J Haematol 2009;145:121-127
13. Siegerink B, Meltzer ME, de Groot PG, Algra A, Lisman T, Rosendaal FR. Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study. Br J Haematol 2012;156:252-258
14. Cannarozzi DB, Wardlaw SC, McPhedran P. An improved turbidimetric method for plasma fibrinogen. Am JMed Technol 1977;43:211-215
15. Agren A, Wiman B, Stiller V, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006;4:201-208
16. Tijssen P, Kurstak E. Highly ef ficient and simple methods for the preparation of peroxidase and active peroxidase-antibody conjugates for enzyme immunoassays. Anal Biochem 1984;136:451-457
17. Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis 2007;18:657-660 (Pubitemid 47479416)
18. Carter AM, Cymbalista CM, Spector TD, Grant PJ; EuroCLOT Investigators. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007;27:2783-2789 (Pubitemid 350158937)
19. Wold S, Sjöström M, Eriksson L. PLS-Regression: a basic tool of chemometrics. J Chemometrics 2001;58:109-130 (Pubitemid 33033283)
20. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006;19:1293-1299
21. Wiman B, Nilsson T, Cedergren B. Studies on a form of alpha 2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen. Thromb Res 1982;28:193-199 (Pubitemid 13253527)
22. Griffin GC, Mammen EF, Sokol RJ, Perrotta AL, Stoyanovich A, Abildgaard CF. Alpha 2-antiplasmin deficiency. An overlooked cause of hemorrhage. Am J Pediatr Hematol Oncol 1993;15:328-330 (Pubitemid 23217962)
23. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010;116:529-536
24. Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006;49:1071-1080
25. Alessi MC, Nicaud V, Scroyen I, et al.; DESIR Study Group. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort. Thromb Haemost 2011;106:416-422
26. Grant MB, Fitzgerald C, Guay C, Lottenberg R. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus. Metabolism 1989;38:901-907 (Pubitemid 19229971)
27. Laing SP, Swerdlow AJ, Carpenter LM, et al. Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 2003;34:418-421 (Pubitemid 36206341)
28. Ossei-Gerning N, Wilson IJ, Grant PJ. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost 1998;79:736-740 (Pubitemid 28163845)
29. Kilpatrick ES, Rigby AS, Atkin SL. The relationship between mean glucose and HbA1c in premenopausalwomen comparedwith males in the Diabetes Control and Complications Trial. Diabet Med 2008;25:112-113
30. Gerstl EM, Rabl W, Rosenbauer J, et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr 2008;167:447-453 (Pubitemid 351322480)
31. Avitabile NA, Banka A, Fonseca VA. Glucose control and cardiovascular outcomes in individuals with diabetes mellitus: lessons learned from the megatrials. Heart Fail Clin 2012;8:513-522
32. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 2010;33:1640-1646
33. Williams KV, Erbey JR, Becker D, Orchard TJ; The Epidemiology of Diabetes Complications Study. Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. Diabetes Care 1999;22:1084-1091 (Pubitemid 29293960)
34. Walmsley D, Hampton KK, Grant PJ. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabet Med 1991;8:954-959
35. Bernot D, Stalin J, Stocker P, et al. Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase. J Cell Sci 2011;124:1224-1230
36. Agren A, Kolmert T, Wiman B, Schulman S. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thromb Res 2007;119:715-721 (Pubitemid 46441426)
37. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypo fibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010;116:113-121
38. Svensson J, Bergman AC, Adamson U, Blombäck M, Wallén H, Jörneskog G. Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study. Biochem Biophys Res Commun 2012;421:335-342
39. Diebold I, Kraicun D, Bonello S, Görlach A. The 'PAI-1 paradox' in vascular remodeling. Thromb Haemost 2008;100:984-991
40. Engelse MA, Hanemaaijer R, Koolwijk P, van Hinsbergh VW. The fibrinolytic system and matrix metalloproteinases in angiogenesis and tumor progression. Semin Thromb Hemost 2004;30:71-82 (Pubitemid 38457302)